Novel quinuclidinone derivatives induce apoptosis in lung cancer via sphingomyelinase pathways

Drug Research

Volumn 63, Issue 7, 2013, Pages 362-369

  Malki, A ^a   Fathy, L ^a   El Ashry, E S H ^a  

^a Alexandria University Faculty Of Science   (Egypt)

Author keywords

apoptosis; cell cycle; lung cancer; p53 null cells; quinuclidinone derivatives

Indexed keywords

2 THIOAMIDO[3,4 B]PYRAZOLOQUINUCLIDINE; 2,2 BISHYDROXYMETHYL 3 QUINUCLIDINONE; CASPASE 9; CYCLIN E; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROCASPASE 3; QUINUCLIDINE DERIVATIVE; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LARGE CELL CARCINOMA; LUNG CARCINOMA; NICK END LABELING; WESTERN BLOTTING;

EID: 84881251590     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1341463     Document Type: Article

References (34)

1. Jemal A., Thomas A., Murray T. et al. Cancer statistics. CA Cancer J Clin: 2005; 52 23 27
2. Carney D. N. Lung cancer - time to move on from chemotherapy. N Engl J Med: 2002; 346 126 128
3. Thomas P., Rubinstein L. Cancer recurrence after resection. T1 N0 non-small cell lung cancer. Lung Cancer Study Group Ann Thorac Surg: 1990; 49 242 246
4. Travis W. D., Travis L. B., Devesa S. S. Lung cancer. Cancer: 1995; 75 191 192
5. Dunst J. Role of radiotherapy in small cell lung cancer. Lung Cancer: 2001; 33 137 141
6. Cohen V., Khuri F. R. Chemoprevention of lung cancer. Curr Opin Pulm Med: 2004; 10 279 283
7. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell: 2000; 100 57 70
8. Liscovitch M., Cantley L. C. Lipid second messengers. Cell: 1994; 77 329 334
9. Saddoughi S. A., Song P., Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem: 2008; 49 413 440
10. Smyth M. L., Obeid L. M., Hannun Y. A. Ceramide a novel lipid mediator of apoptosis. Adv Pharmacol: 1997; 41 33 54
11. Sonnino S., ureli M., Loberto N. et al. Fine tuning of cell functions through remodeling of glycosphingolipids by plasma membrane-associated glycohydrolases. FEBS Lett: 2010; 584 1914 1922
12. Lacour S., Hammann A., Grazide S. et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res: 2004; 64 3593 3598
13. Morita Y., Perez G. I., Paris F. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med: 2000; 6 1109 1114
14. Oliver L., Vallette F. M. The role of caspases in cell death and differentiation. Drug Resist Updat: 2005; 8 163 170
15. Fischer U., Janicke R. U., Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ: 2003; 10 76 100
16. Bykov V. J., Issaeva N., Selivanova G. et al. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis: 2002; 12 2011 2018
17. Bykov V., Issaeva N., Shilov N. A. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med: 2000; 8 282 288
18. Malki A., Bergmeier S. Differential Apoptotic Effects of Novel Quinuclidinone analogs 8a and 8b in Normal and Lung Cancer Cell Lines. Anticancer Res: 2011; 31 1345 1358
19. Malki A., Bergmeier S. Novel Quinuclidinone Derivative 8a Induced Apoptosis in Human MCF-7 Breast Cancer Cell Lines. Anticancer Res: 2011; 31 871 881
20. Nielsen A. T. Systems with bridgehead nitrogen. B-Ketols of the 1-azabicyclo[2.2.2]octane series. J Org Chem: 1966; 31 1053 1059
21. Bondarenko V. A., Mikhlina E. E., Filipenko T. et al. Reaction of 2-methylene-3-oxoquinuclidine with bifunctional nucleophilic reagents. Khim Getero Soed: 1979; 10 1393 1397
22. Vazquez A., Bond E. E., Levine A. J. et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov: 2008; 7 979 987
23. Benner S. E., Hong W. K. Clinical chemoprevention: developing a cancer prevention strategy. J Natl Cancer Inst (Bethesda): 1993; 85 1446 1447
24. Elledge S. J. Cell cycle checkpoints: preventing an identity crisis. Science: 1996; 274 1664 1672
25. Longley D. B., Johnston P. G. Molecular mechanisms of drug resistance. J Pathol: 2005; 205 275 292
26. Lampson M. A., Kapoor T. M. Unraveling cell division mechanisms with small-molecule inhibitors. Nat Chem Biol: 2006; 2 19 27
27. Yu Q., La Rose J., Zhang H. et al. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res: 2002; 62 5743 5748
28. Aldridge D. R., Radford I. R. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res: 1998; 58 2817 2824
29. Gulbins E., Bissonnette R., Mahboubi A. et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity: 1995; 2 341 351
30. Hannun Y. A., Obeid L. M. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci: 1995; 20 73 77
31. Jarvis W. D., Kolesnick R. N., Fornari F. A. et al. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA: 1994; 91 73 77
32. Hannun Y. A., Linardic V. Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids. Biochimica et Biophysica Acta: 1993; 1154 223 236
33. Oliver L., Vallette F. M. The role of caspases in cell death and differentiation. Drug Resist Update: 2005; 8 163 170
34. Fischer U., Janicke R. U., Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ: 2003; 10 76 100